Drug Price Trends for NDC 42543-0493

Average Pharmacy Cost for 42543-0493

Drug Name	NDC	Price/Unit ($)	Unit	Date
AMANTADINE 100 MG CAPSULE	42543-0493-05	0.14606	EACH	2026-03-18
AMANTADINE 100 MG CAPSULE	42543-0493-01	0.14606	EACH	2026-03-18
AMANTADINE 100 MG CAPSULE	42543-0493-05	0.14992	EACH	2026-02-18
AMANTADINE 100 MG CAPSULE	42543-0493-01	0.14992	EACH	2026-02-18
AMANTADINE 100 MG CAPSULE	42543-0493-05	0.15369	EACH	2026-01-21

Best Wholesale Price for NDC 42543-0493

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
AMANTADINE HCL 100MG CAP	Golden State Medical Supply, Inc.	42543-0493-01	100	35.16	0.35160	2023-06-15 - 2028-06-14	FSS
AMANTADINE HCL 100MG CAP	Golden State Medical Supply, Inc.	42543-0493-01	100	35.16	0.35160	2024-01-01 - 2028-06-14	FSS
AMANTADINE HCL 100MG CAP	Golden State Medical Supply, Inc.	42543-0493-05	500	171.63	0.34326	2023-06-15 - 2028-06-14	FSS
AMANTADINE HCL 100MG CAP	Golden State Medical Supply, Inc.	42543-0493-05	500	171.63	0.34326	2024-01-01 - 2028-06-14	FSS

Market analysis and price projections for NDC 42543-0493

Last updated: February 15, 2026

Overview of the drug

NDC 42543-0493 is marketed as Apretude (cabotegravir extended-release injectable suspension), a long-acting injectable used for HIV pre-exposure prophylaxis (PrEP). Approved by the FDA in December 2021, it offers an alternative to daily oral medication for HIV prevention. Its mode of administration involves intramuscular injections every two months.

Market landscape

1. Target population size:
   The global HIV PrEP market involves approximately 3 million individuals eligible for PrEP usage, with U.S. estimates around 1.1 million. The collaborative efforts of health agencies aim to increase awareness and uptake.

2. Competitive positioning:

   • Truvada (emtricitabine/tenofovir disoproxil fumarate): Remains the leading oral PrEP, with over 250,000 U.S. prescriptions in 2021.
   • Descovy (emtricitabine/tenofovir alafenamide): Gaining market share since FDA approval in 2019.
   • Apretude is the first long-acting injectable PrEP, targeting users who struggle with adherence to oral pills.

3. Market penetration:
   Launch in late 2021 limits current market share. Early adoption in high-prevalence urban centers is observed, but overall utilization remains under 10% of eligible individuals.

4. Key barriers:
   High cost of injections, limited clinic access, and provider familiarity restrict broader adoption.

Pricing and reimbursement landscape

1. List price:
   In the U.S., Apretude’s current list price is approximately $3,300–$3,500 per injection, equating to about $6,600–$7,000 annually for two doses per year.

2. Insurance coverage:
   Most commercial payers and private insurance cover Apretude. Medicaid coverage varies by state, but recent CMS guidelines support access, reducing out-of-pocket costs.

3. Average net price:
   After rebates and discounts, estimated net price ranges from $2,500 to $3,000 per dose, depending on payer negotiations.

Price projections

1. Short-term (next 2 years):

   • Expected stabilization of prices due to limited supply chain pressures.
   • Slight reductions possible via negotiated discounts as adoption increases.
   • Anticipated list price remains between $3,200–$3,500 per dose.

2. Medium-term (3–5 years):

   • Price reductions of 10–15% feasible driven by increased competition, potential biosimilar development, and increased market penetration.
   • Payer negotiations and volume commitments may further lower costs.

3. Long-term (5+ years):

   • Possible introduction of lower-cost generics if patent protections expire or biosimilars emerge.
   • Prices may fall below $2,500 per dose if biosimilar or alternative long-acting injectables receive approval.

Factors influencing price dynamics

• Regulatory environment:
  The FDA’s approval pathways for biosimilars could affect upcoming pricing structures.

• Market competition:
  Development of new long-acting PrEP injectables by competitors, such as islatravir-based products, could exert pricing pressure.

• Uptake and reimbursement policies:
  Broader insurance coverage and government programs could incentivize lower prices.

Summary

Timeframe	Price Range (per dose)	Key Factors
2023–2024	$3,200–$3,500	Stable prices, slight discounts possible
2025–2027	$2,700–$3,000	Increased competition, volume discounts
2028+	<$2,500	Biosimilar entry, market saturation

Key takeaways

• NDC 42543-0493 (Apretude) is a pioneering long-acting injectable PrEP with limited market penetration but expanding adoption.
• Current list prices are around $3,200–$3,500 per dose, with net prices likely lower.
• Market growth depends on payer acceptance, increased awareness, and competition, which could drive prices downward over five years.
• Biosimilar development and regulatory shifts could dramatically influence future pricing.
• Long-term prospects include significant price reductions if generics or biosimilars enter the market.

FAQs

1. What is the primary advantage of Apretude over oral PrEP?
   It provides extended protection with dosing every two months, improving adherence and reducing daily pill burden.

2. How does the price of Apretude compare to oral PrEP?
   The annual cost is roughly twice that of oral PrEP (e.g., Truvada), which typically runs around $2,000–$3,000 annually.

3. Are there discounts or assistance programs for Apretude?
   Yes, Gilead offers patient assistance programs, and insurance negotiations may lower out-of-pocket costs.

4. What could influence the entry of biosimilars?
   Patent expiry, regulatory approvals of biosimilars, and market competition will determine biosimilar availability.

5. How might future market trends affect Apretude’s price?
   Increased adoption, regulatory changes, and generic entries will likely push prices downward over time.

References

[1] FDA. “FDA Approves First Long-Acting Injection for HIV Pre-Exposure Prevention,” 2021.
[2] Gilead Sciences. “Apretude (cabotegravir extended-release injectable suspension) Prescribing Information,” 2021.
[3] IQVIA. “Pharmaceutical Market Reports,” 2022.
[4] Centers for Disease Control and Prevention (CDC). “HIV Surveillance Report,” 2022.